Cardea Services

cardeaservices.org

Cardea is a national organization with offices in Oakland, California; Austin, Texas; and Seattle, Washington. For more than 40 years, we have provided training, organizational development, and research and evaluation services to improve organizations’ abilities to deliver accessible, high quality, culturally proficient, and compassionate services to their clients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

PHARMABCINE TO PRESENT UPDATED INTERIM DATA FROM THE ONGOING PHASE IB TRIAL OF OLINVACIMAB AND PEMBROLIZUMAB COMBINATION THERAPY

PharmAbcine | December 08, 2020

news image

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.
Read More

Cell and Gene Therapy

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

news image

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More

PHANES THERAPEUTICS REVEALS A NEW BISPECIFIC ANTIBODY TECHNOLOGY PLATFORM AT BIO DIGITAL 2020

Phanes Therapeutics | June 16, 2020

news image

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure. The technology was presented at the BIO Digital 2020."The beauty of the PACbodyTM bispecific antibody platform is that it's a 'pl...

Read More

Industrial Impact

GUARDANT HEALTH RECEIVES REGULATORY APPROVAL FROM SINGAPORE'S HEALTH SCIENCES AUTHORITY FOR GUARDANT360® CDX BLOOD TEST FOR PATIENTS

PRNewswire | May 30, 2023

news image

Guardant Health, Inc. announced that Singapore's Health Sciences Authority has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer with epidermal growth factor receptor alterations who may benefit from treatment with TAG...

Read More
news image

Research

PHARMABCINE TO PRESENT UPDATED INTERIM DATA FROM THE ONGOING PHASE IB TRIAL OF OLINVACIMAB AND PEMBROLIZUMAB COMBINATION THERAPY

PharmAbcine | December 08, 2020

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.
Read More

news image

Cell and Gene Therapy

PDS BIOTECH REPORTS AN INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS ...

Read More
news image

PHANES THERAPEUTICS REVEALS A NEW BISPECIFIC ANTIBODY TECHNOLOGY PLATFORM AT BIO DIGITAL 2020

Phanes Therapeutics | June 16, 2020

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure. The technology was presented at the BIO Digital 2020."The beauty of the PACbodyTM bispecific antibody platform is that it's a 'pl...

Read More
news image

Industrial Impact

GUARDANT HEALTH RECEIVES REGULATORY APPROVAL FROM SINGAPORE'S HEALTH SCIENCES AUTHORITY FOR GUARDANT360® CDX BLOOD TEST FOR PATIENTS

PRNewswire | May 30, 2023

Guardant Health, Inc. announced that Singapore's Health Sciences Authority has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling in patients with advanced solid cancers. The Guardant360 CDx test was also approved as a companion diagnostic to identify patients with advanced non-small cell lung cancer with epidermal growth factor receptor alterations who may benefit from treatment with TAG...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us